Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China

F1000Research

Volumn 9, Issue , 2020, Pages

  Kruse, Robert L ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

2019 nCoV; ACE2; Coronavirus; Neutralizing antibody; Outbreak; Wuhan

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; OLIGONUCLEOTIDE; RECOMBINANT PROTEIN; VIRUS RNA; COVID-19; DIPEPTIDYL CARBOXYPEPTIDASE; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2;

BIOLOGICAL ACTIVITY; CHINA; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; DRUG RECEPTOR BINDING; DRUG REPOSITIONING; GENE TARGETING; HUMAN; IMMUNE SYSTEM; NOTE; PASSIVE IMMUNIZATION; QUARANTINE; SARS-RELATED CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; TREATMENT PLANNING; VIRUS IMMUNITY; VIRUS MUTATION; VIRUS NEUTRALIZATION; BETACORONAVIRUS; COMPASSIONATE USE; DRUG EFFECT; EPIDEMIC; EPIDEMIOLOGY; VIRUS PNEUMONIA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BETACORONAVIRUS; CHINA; COMPASSIONATE USE TRIALS; CORONAVIRUS INFECTIONS; DISEASE OUTBREAKS; DRUG REPOSITIONING; HUMANS; OLIGONUCLEOTIDES; PEPTIDYL-DIPEPTIDASE A; PNEUMONIA, VIRAL;

EID: 85080839534     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.22211.2     Document Type: Note

References (74)

1. Zhu N, Zhang D, Wang W, et al.: A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; NEJMoa2001017.
2. Ksiazek TG, Erdman D, Goldsmith CS, et al.: A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20): 1953-1966.
3. Zaki AM, van Boheemen S, Bestebroer TM, et al.: Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012; 367(19): 1814-1820.
4. Stadler K, Masignani V, Eickmann M, et al.: SARS--beginning to understand a new virus. Nat Rev Microbiol. 2003; 1(3): 209-218.
5. Chan JF, Yuan S, Kok KH, et al.: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; pii: S0140-6736(20)30154-9.
6. Huang C, Wang Y, Li X, et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; pii: S0140-6736(20)30183-5.
7. Cheng VCC, Wong SC, To KKW, et al.: Preparedness and proactive infection control measures against the emerging Wuhan coronavirus pneumonia in China. J Hosp Infect. 2020; pii: S0195-6701(20)30034-7.
8. Svoboda T, Henry B, Shulman L, et al.: Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto. N Engl J Med. 2004; 350(23): 2352-2361.
9. Fischer WA 2nd, Weber D, Wohl DA: Personal Protective Equipment: Protecting Health Care Providers in an Ebola Outbreak. Clin Ther. 2015; 37(11): 2402-2410.
10. Avendano M, Derkach P, Swan S: Clinical course and management of SARS in health care workers in Toronto: a case series. CMAJ. 2003; 168(13): 1649-1660.
11. Uyeki TM, Mehta AK, Davey RT Jr, et al.: Clinical Management of Ebola Virus Disease in the United States and Europe. N Engl J Med. 2016; 374(7): 636-646.
12. Henao-Restrepo AM, Camacho A, Longini IM, et al.: Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017; 389(10068): 505-518.
13. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al.: Vesicular stomatitis virusbased ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008; 4(11): e1000225.
14. Tortorici MA, Veesler D: Structural insights into coronavirus entry. Adv Virus Res. 2019; 105: 93-116.
15. Casadevall A, Pirofski LA: The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases. PLoS Pathog. 2015; 11(4): e1004717.
16. Shin YW, Chang KH, Hong GW, et al.: Selection of Vaccinia Virus-Neutralizing Antibody from a Phage-Display Human-Antibody Library. J Microbiol Biotechnol. 2019; 29(4): 651-657.
17. Keck ZY, Wang Y, Lau P, et al.: Isolation of HCV Neutralizing Antibodies by Yeast Display. Methods Mol Biol. 2019; 1911: 395-419.
18. Elshabrawy HA, Coughlin MM, Baker SC, et al.: Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS One. 2012; 7(11): e50366.
19. Tripathi NK, Shrivastava A: Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development. Front Bioeng Biotechnol. 2019; 7: 420.
20. Schmidt R, Beltzig LC, Sawatsky B, et al.: Generation of therapeutic antisera for emerging viral infections. NPJ Vaccines. 2018; 3: 42-10.
21. Jahrling PB, Geisbert J, Swearengen JR, et al.: Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl. 1996; 11: 135-140.
22. Goto M, Kuribayashi K, Umemori Y, et al.: High prevalence of human anti-mouse antibodies in the serum of colorectal cancer patients. Anticancer Res. 2010; 30(10): 4353-4356.
23. Qureshi A, Tantray VG, Kirmani AR, et al.: A review on current status of antiviral siRNA. Rev Med Virol. 2018; 28(4): e1976.
24. Youngren-Ortiz SR, Gandhi NS, España-Serrano L, et al.: Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems. Kona. 2016; 33: 63-85.
25. Dunning J, Sahr F, Rojek A, et al.: Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. PLoS Med. 2016; 13(4): e1001997.
26. Thi EP, Mire CE, Lee AC, et al.: Lipid nanoparticle siRNA treatment of Ebola- virus-Makona-infected nonhuman primates. Nature. 2015; 521(7552): 362-365.
27. Thi EP, Lee AC, Geisbert JB, et al.: Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA. Nat Microbiol. 2016; 1(10): 16142.
28. Tsai CH, Lee PY, Stollar V, et al.: Antiviral therapy targeting viral polymerase. Curr Pharm Des. 2006; 12(11): 1339-1355.
29. Anderson J, Schiffer C, Lee SK, et al.: Viral protease inhibitors. Handb Exp Pharmacol. 2009; 189: 85-110.
30. Litterman N, Lipinski C, Ekins S: Small molecules with antiviral activity against the Ebola virus [version 1; peer review: 2 approved]. F1000Res. 2015; 4: 38.
31. Dodd LE, Follmann D, Proschan M, et al.: A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. Sci Transl Med. 2019; 11(520): pii: eaaw1049.
32. Chu CM, Cheng VC, Hung IF, et al.: Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59(3): 252-256.
33. Sheahan TP, Sims AC, Leist SR, et al.: Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020; 11(1): 222.
34. Li CC, Wang XJ, Wang HR: Repurposing host-based therapeutics to control coronavirus and influenza virus. Drug Discov Today. 2019; 24(3): 726-736.
35. Dyall J, Coleman CM, Hart BJ, et al.: Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014; 58(8): 4885-4893.
36. Mire CE, Geisbert JB, Agans KN, et al.: Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. J Infect Dis. 2016; 214(suppl 3): S367-S374.
37. Marano G, Vaglio S, Pupella S, et al.: Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016; 14(2): 152-157.
38. Kraft CS, Hewlett AL, Koepsell S, et al.: The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. Clin Infect Dis. 2015; 61(4): 496-502.
39. Walker LM, Burton DR: Passive immunotherapy of viral infections: 'super-antibodies' enter the fray. Nat Rev Immunol. 2018; 18(5): 297-308.
40. PREVAIL II Writing Group, Multi-National PREVAIL II Study Team, Davey RT Jr, et al.: A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N Engl J Med. 2016; 375(15): 1448-1456.
41. Zhou P, Yang XL, Wang XG, et al.: Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv. 2020; 2020.01.22.914952.
42. Li W, Moore MJ, Vasilieva N, et al.: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426(6965): 450-454.
43. Karakus U, Pohl MO, Stertz S: Breaking the convention: Sialoglycan variants, Co-receptors and Alternative Receptors for Influenza A Virus Entry. J Virol. 2019; pii: JVI.01357-19.
44. Wong SK, Li W, Moore MJ, et al.: A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem. 2004; 279(5): 3197-3201.
45. Arbabi-Ghahroudi M: Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook. Front Immunol. 2017; 8: 1589.
46. Xia C, Gautam A: Biopharma CRO industry in China: landscape and opportunities. Drug Discov Today. 2015; 20(7): 794-798.
47. Du L, Kou Z, Ma C, et al.: A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One. 2013; 8(12): e81587.
48. Wang X, Mathieu M, Brezski RJ: IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2018; 9(1): 63-73.
49. Sondermann P, Szymkowski DE: Harnessing Fc receptor biology in the design of therapeutic antibodies. Curr Opin Immunol. 2016; 40: 78-87.
50. Desmyter A, Farenc C, Mahony J, et al.: Viral infection modulation and neutralization by camelid nanobodies. Proc Natl Acad Sci U S A. 2013; 110(15): E1371-9.
51. Koch K, Kalusche S, Torres JL, et al.: Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers. Sci Rep. 2017; 7(1): 8390-15.
52. He Y, Zhou Y, Liu S, et al.: Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004; 324(2): 773-781.
53. Gu J, Korteweg C: Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007; 170(4): 1136-1147.
54. Kuba K, Imai Y, Rao S, et al.: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005; 11(8): 875-879.
55. Sui J, Li W, Murakami A, et al.: Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A. 2004; 101(8): 2536-2541.
56. Moore MJ, Dorfman T, Li W, et al.: Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J Virol. 2004; 78(19): 10628-10635.
57. Imai Y, Kuba K, Rao S, et al.: Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436(7047): 112-116.
58. Gu H, Xie Z, Li T, et al.: Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci Rep. 2016; 6: 19840.
59. Zou Z, Yan Y, Shu Y, et al.: Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun. 2014; 5: 3594.
60. Haschke M, Schuster M, Poglitsch M, et al.: Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet. 2013; 52(9): 783-792.
61. Khan A, Benthin C, Zeno B, et al.: A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017; 21(1): 234.
62. Li F, Li W, Farzan M, et al.: Structure of SARS coronavirus spike receptorbinding domain complexed with receptor. Science. 2005; 309(5742): 1864-1868.
63. Liu P, Wysocki J, Souma T, et al.: Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney Int. 2018; 94(1): 114-125.
64. Yasui F, Kohara M, Kitabatake M, et al.: Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus. Virology. 2014; 454-455: 157-168.
65. Glowacka I, Bertram S, Herzog P, et al.: Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J Virol. 2010; 84(2): 1198-1205.
66. Li W, Zhang C, Sui J, et al.: Receptor and viral determinants of SARS- coronavirus adaptation to human ACE2. EMBO J. 2005; 24(8): 1634-1643.
67. Chamow SM, Duliege AM, Ammann A, et al.: CD4 immunoadhesins in anti-HIV therapy: new developments. Int J Cancer Suppl. 1992; 7: 69-72.
68. Shearer WT, Israel RJ, Starr S, et al.: Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J Infect Dis. 2000; 182(6): 1774-1779.
69. Jacobson JM, Lowy I, Fletcher CV, et al.: Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis. 2000; 182(1): 326-329.
70. Gardner MR, Kattenhorn LM, Kondur HR, et al.: AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature. 2015; 519(7541): 87-91.
71. Gardner MR, Fellinger CH, Kattenhorn LM, et al.: AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges. Sci Transl Med. 2019; 11(502): pii: eaau5409.
72. Shao Z, Shrestha K, Borowski AG, et al.: Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure. J Card Fail. 2013; 19(9): 605-610.
73. Wan Y, Shang J, Sun S, et al.: Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol. 2019; pii: JVI.02015-19.
74. Raj VS, Mou H, Smits SL, et al.: Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013; 495(7440): 251-254.